Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival

Compared with surgery alone, postoperative adjuvant radiotherapy (RT) improves relapse-free survival of patients with early-stage breast cancer. We evaluated the long-term overall and disease-free survival rates of neoadjuvant (presurgical) versus adjuvant RT in early-stage breast cancer patients. W...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research : BCR 2017-06, Vol.19 (1), p.75-75, Article 75
Main Authors: Poleszczuk, Jan, Luddy, Kimberly, Chen, Lu, Lee, Jae K, Harrison, Louis B, Czerniecki, Brian J, Soliman, Hatem, Enderling, Heiko
Format: Article
Language:English
Subjects:
Aged
Biomarkers, Tumor
Breast cancer
Breast Neoplasms - epidemiology
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - radiotherapy
Cancer therapies
Care and treatment
Chemotherapy
Combined Modality Therapy
Development and progression
Disease-free survival
Early-stage breast cancer
Epidemiology
Female
Humans
Immune response
Immunotherapy
Lymphatic system
Mammography
Mastectomy
Medical diagnosis
Melanoma
Metastasis
Methods
Middle Aged
Mortality
Neoadjuvant Therapy
Neoplasm Staging
Overall survival
Patient outcomes
Patients
Postoperative radiotherapy
Preoperative radiotherapy
Prognosis
Proportional Hazards Models
Radiation therapy
Radiotherapy
Radiotherapy, Adjuvant
SEER Program
Software
Surgery
Surveillance
Survival
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Compared with surgery alone, postoperative adjuvant radiotherapy (RT) improves relapse-free survival of patients with early-stage breast cancer. We evaluated the long-term overall and disease-free survival rates of neoadjuvant (presurgical) versus adjuvant RT in early-stage breast cancer patients. We used the Surveillance, Epidemiology, and End Results (SEER) database provided by the National Institutes of Health to derive an analytic dataset of 250,195 female patients with early-stage breast cancer who received RT before (n = 2554; 1.02%) or after (n = 247,641; 98.98%) surgery. Disease-free survival, defined as time to diagnosis of a second primary tumor at any location, was calculated from automated patient identification matching of all SEER records. Partial and complete mastectomies were performed in 94.4% and 5.6% of patients, respectively. In the largest cohort of estrogen receptor-positive women who underwent partial mastectomy, the HR of developing a second primary tumor after neoadjuvant compared with adjuvant RT was 0.64 (95% CI 0.55-0.75; P 
ISSN:1465-542X
1465-5411
1465-542X
DOI:10.1186/s13058-017-0870-1